Transcenta Debuts Encouraging Phase II Data from First-line

/PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities...

Related Keywords

China , Shanghai , Guangzhou , Guangdong , Hangzhou , Zhejiang , Princeton , Massachusetts , United States , Boston , Beijing , Suzhou , Jiangsu , Los Angeles , Product Development Center , Prnewswire Transcenta Holding Limited , Transcenta Immune Tolerance Breaking Technology , Clinical Development Centers In Princeton , Group Headquarters , Translational Research Center , Holding Limited , Clinical Oncology Volume , Immune Tolerance Breaking Technology , Orphan Drug Designation , Manufacturing Facility , Clinical Development Centers , External Partnering Center , Suzhou Industrial ,